ACTA1 and Hepatic fibrosis: This is why α-SMA and Coll are considered one of the molecular markers of HSC activation, and therefore, HSC is considered as a therapeutic target for liver fibrosis and cirrhosis (Wu and Zern, 2000; Bataller and Brenner, 2001).